12 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jun 25, 2026 through Jul 27, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
New CRISPR gene-editing research indicates a method to improve the immune system's ability to detect and target prostate cancer tumors.
Medical experts and patient accounts highlight an increasing prevalence of early-onset colorectal cancer and the risks associated with missed symptoms.
Scientific research into the impact of creatine supplementation on cancer development is sparking conflicting reports regarding its potential risks and benefits.
A leading oncologist is challenging traditional wellness norms by promoting six habits for longevity, including the surprising inclusion of ice cream.
A new blood gene test has demonstrated the ability to detect 90% of early-stage pancreatic cancers, a disease with a 13% survival rate.
A second PSMA PET scan may alter the treatment course for nearly 50% of prostate cancer patients, according to new study data.
The oncology community mourns the death of Maura Gillison, a doctor who transformed the treatment of mouth and throat cancers.
Sanofi's Sarclisa becomes the first cancer drug approved by the FDA for delivery via an on-body injector for multiple myeloma.
A new global report warns of a significant surge in cancer cases worldwide over the coming decades.
Experimental cancer treatment Daraxonrasib is gaining momentum as regulators fast-track review and clinical data suggests potential advancements in patient care.
Novartis is expanding its cancer-drug pipeline through the acquisition of U.K.-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.
An experimental drug targeting pancreatic cancer is showing promising survival gains in clinical trials.